Skip to content

VitaSmart HOPE System: Bridge to HOPE Registry

A Post-market, Multi-center Clinical Registry to Evaluate the Safety, Effectiveness, and Real-World Utilization of the VitaSmart Hypothermic Oxygenated Perfusion (HOPE) System (Bridge to HOPE Registry)

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07578441
Enrollment
5000
Registered
2026-05-11
Start date
2026-09-01
Completion date
2033-12-01
Last updated
2026-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Liver DIsease, Liver Failure

Keywords

Liver preservation, VitaSmart, Hypothermic Oxygenated Perfusion, HOPE, Hypothermic Oxygenated Machine Perfusion, Liver transplantation

Brief summary

This is a post-market, multicenter, single-arm, observational registry evaluating real-world use of the VitaSmart HOPE System under standard of care conditions. Clinical data from up to 5000 transplant recipients will be included in the registry at up to 20 U.S. transplant centers. This registry will include clinical data collected retrospectively from medical records of recipients already transplanted before the initiation of the registry and any new recipients of livers that meet donor selection criteria. This registry introduces no contact with the transplant recipient and registry participants will follow standard of care. Data will be collected through up to 5 years of standard of care clinical follow-up. This registry represents minimal risk to the transplant recipients being studied. The participants included in this registry will have undergone transplant surgery with a deceased donor liver graft that was perfused using the VitaSmart HOPE System, a medical device that is cleared by the Food and Drug Administration (FDA) for commercial use in the U.S. All perfusions of deceased donor liver grafts will be performed in accordance with standard medical practice. The objectives of this registry is to Evaluate the safety and efficacy of HOPE prior to liver transplantation in real-world clinical settings.

Interventions

DEVICEhypothermic oxygenated perfusion therapy of a donor liver under standard of care conditions

Observational, real-world use of the VitaSmart HOPE System with a donor liver graft under standard of care conditions.

Sponsors

Bridge to Life Ltd.
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1\. Liver graft accepted for transplant and perfused using the VitaSmart HOPE System

Exclusion criteria

1. Liver from a living donor 2. Split liver transplant

Design outcomes

Primary

MeasureTime frameDescription
Number of Recipients alive with functioning graft at 1-year post-transplant1-year post-transplantNumber of Recipients alive with functioning graft at 1-year post-transplant (absence of graft failure or death for liver related reasons)

Countries

United States

Contacts

STUDY_CHAIRDavid Foley, MD

University of Wisconsin, Madison

STUDY_CHAIRAndrea Schlegel, MD, MBA

The Cleveland Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 23, 2026